Tianjin Medical University Cancer Institute and Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 48 Carcinoma, Non-Small-Cell Lung studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 23 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 35Phase 3 5Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation DeviceRecruitingNCT07561567
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based ChemotherapyRecruitingNCT07548060Phase 2
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureRecruitingNCT07528274Phase 2
• Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung CancerRecruitingNCT07505173Phase 2
• Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLCNot yet recruitingNCT07438600Phase 2
• Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyNot yet recruitingNCT07365410Phase 2
• WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLCRecruitingNCT07330050Phase 2
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesRecruitingNCT07304739Phase 2
• Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCRecruitingNCT06939127Phase 2
• Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLCNot yet recruitingNCT06890182Phase 2
• Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT06704620Phase 3
• Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer PatientsNot yet recruitingNCT06697990Phase 2
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
• To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
• Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.RecruitingNCT06317324
• Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)RecruitingNCT06221670Phase 2
• A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsNot yet recruitingNCT06143735Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
• Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
• Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
• Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung CancerActive, not recruitingNCT04836728Phase 2
• Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
• Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard TreatmentsStatus unknownNCT04825925Not applicable
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownNCT04797806Phase 3
• Almonertinib With Chemotherapy in mEGFR NSCLCStatus unknownNCT04646824Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLCStatus unknownNCT04193098Phase 1
• Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion MutationStatus unknownNCT04063462Phase 2
• Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790MStatus unknownNCT04029350Phase 2
• Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLCStatus unknownNCT03987867Phase 1
• Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC PatientsStatus unknownNCT03874000Phase 2
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedNCT03736837Phase 2
• Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary LobectomyStatus unknownNCT02916147Not applicable
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
• Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLCCompletedNCT02497118Phase 4
• Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFRStatus unknownNCT01744925Phase 2
• Erlotinib in Post Radical Operation NSCLC Patients With EGFR MutationStatus unknownNCT01683175Phase 2
• Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung CancerCompletedNCT01631357Phase 2/3
• Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC PatientsStatus unknownNCT01393080Not applicable
• Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)CompletedNCT01099124Not applicable
• Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)SuspendedNCT00986284Phase 2
• Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung CancerStatus unknownNCT00973310Phase 2